These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38924626)

  • 1. Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
    Sutton TL; Billingsley KG; Johnson AJ; Corless CL; Blanke CD; Heinrich MC; Mayo SC
    J Surg Oncol; 2024 Jul; 130(1):40-46. PubMed ID: 38924626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
    JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
    Wu X; Li J; Xu W; Gao J; Li Y; Shen L
    Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
    Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
    Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
    Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
    JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
    Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y; Hao H; Guo L; Yang G; Zhang X
    Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
    Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
    Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study.
    Bertsimas D; Margonis GA; Sujichantararat S; Koulouras A; Ma Y; Antonescu CR; Brennan MF; Martín-Broto J; Tang S; Rutkowski P; Kreis ME; Beyer K; Wang J; Bylina E; Sobczuk P; Gutierrez A; Jadeja B; Tap WD; Chi P; Singer S
    Lancet Oncol; 2024 Aug; 25(8):1025-1037. PubMed ID: 38976997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.
    Guérin A; Sasane M; Keir CH; Gauthier G; Macalalad AR; Wu EQ; Conley AP
    JAMA Oncol; 2015 Sep; 1(6):797-805. PubMed ID: 26204106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
    Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY
    J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial.
    Joensuu H; Reichardt A; Eriksson M; Hohenberger P; Boye K; Cameron S; Lindner LH; Jost PJ; Bauer S; Schütte J; Lindskog S; Kallio R; Jaakkola PM; Goplen D; Wardelmann E; Reichardt P
    Br J Cancer; 2024 Jul; 131(2):299-304. PubMed ID: 38862742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
    Tang J; Zhao R; Zheng X; Xu L; Wang Y; Feng L; Ren S; Wang P; Zhang M; Xu M
    Medicine (Baltimore); 2018 Jul; 97(29):e11400. PubMed ID: 30024511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
    Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
    Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry.
    Stuart E; Banerjee S; de la Torre J; Wang Y; Scherzer N; Burgoyne AM; Parry L; Fanta PT; Ramamoorthy S; Sicklick JK
    J Surg Oncol; 2019 Sep; 120(4):715-721. PubMed ID: 31297829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Imatinib on Survival and Treatment Trends for Small Bowel and Colorectal Gastrointestinal Stromal Tumors.
    Almaazmi H; Stem M; Lo BD; Taylor JP; Fang SH; Safar B; Efron JE; Atallah C
    J Gastrointest Surg; 2020 Jan; 24(1):98-108. PubMed ID: 31388887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
    Gronchi A; Bonvalot S; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom HJ; van Coevorden F; Penel N; Kopp HG; Duffaud F; Goldstein D; Broto JM; Wardelmann E; Marréaud S; Smithers M; Le Cesne A; Zaffaroni F; Litière S; Blay JY; Casali PG
    JAMA Surg; 2020 Jun; 155(6):e200397. PubMed ID: 32236507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.